Indications
Aflibercept is used together with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with metastatic colorectal cancer (mCRC). It is meant for those whose cancer has become resistant to an oxaliplatin-containing regimen, or has progressed after it.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Aflibercept is a recombinant fusion protein that works as a decoy receptor for two ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It stops these ligands from binding to the endothelial receptors VEGFR-1 and VEGFR-2, so neovascularization is suppressed and vascular permeability goes down. In the end, this slows vision loss or the progression of metastatic colorectal cancer.
Pregnancy & Breastfeeding
Aflibercept is a pregnancy category C medicine. There are no adequate and well-controlled studies of Aflibercept in pregnant women. In rabbits, it was embryotoxic and teratogenic at exposure levels lower than human exposures at the recommended dose, and the fetuses showed more external, visceral and skeletal malformations. So Aflibercept should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It isn't known whether Aflibercept passes into human milk. Many drugs do pass into milk, and Aflibercept could cause serious adverse reactions in nursing infants. For this reason, a decision should be made either to stop nursing or to stop the drug, taking into account how important the drug is to the mother.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.